Carbiotix AB announces the outcome of the exercise of warrants of series TO 2

During the exercise period from and including October 12, 2023, up to and including October 26, 2023, holders of warrants of series TO 2 have had the right to subscribe for one (1) new share in Carbiotix for each warrant of series TO 2 at a price of SEK1.50 per share. No warrants have been exercised and thus no share capital increase or change in the number of shares in the Company has taken place. The number of shares is thus still 20,736,229 and the share capital is SEK 2,073,622.90.

For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se

For more information, please contact:
Erik Deaner, VD
Telefon: +46 (0)73-867 30 85
E-post: erik.deaner@carbiotix.com

About Carbiotix
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome health through a portfolio of prebiotic modulators and diagnostic testing services.

Datum 2023-10-27, kl 11:00
Källa Cision
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!